ISSN: 1859 - 2872
Serum levels of IL-17, IL-23, TNF-α in moderate and severe psoriasis vulgaris before and after narrowband UVB phototherapy
Main Article Content
Keywords
Abstract
Objective: To evaluate immune changes including serum levels of IL-17, IL-23 and TNF-α in patients with moderate and severe psoriasis vulgaris before and after narrowband UVB therapy. Subject and method: 42 patients with moderate and severe psoriasis vulgaris visited the National Dermatology Hospital from January 2017 to June 2019. Patients were treated with NB-UVB 311nm, initial dose based on Fitzpatrick skin types, until reaching PASI75 or the 36th treatment. Levels of IL-17, IL-23 and TNF-α in plasma were measured at baseline and after the end of treatment. Result: The concentrations of IL-17, IL-23 and TNF-α in the serum of patients with moderate and severe psoriasis before and after treatment with narrow band UVB were: 4.6 ± 5.1pg/ml vs 4.5 ± 6.0pg/ml (IL-17); 12.2 ± 12.6 pg/ml vs 13.4 ± 31.0pg/ml (IL-23) and 34.0 ± 64.3pg/ml vs 193.1 ± 856.9pg/ml (TNF-α), respectively. However, these changes were not statistically significant with p>0.05. Conclusion: In this study, we did not observe immunological changes (serum levels of IL-17, IL-23 and TNF-alpha) of psoriasis vulgaris before and after treatment with narrowband UVB phototherapy.
Article Details
References
2. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL (2006) Randomized double-blind trial of the treatment of chronic plaque psoriasis: Efficacy of psoralen–uv-a therapy vs narrowband uv-b therapy. Archives of dermatology 142(7): 836-842.
3. Coimbra S, Oliveira H, Reis F et al (2010) Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy: Psoriasis vulgaris cytokines and PUVA/NB-UVB therapy. British Journal of Dermatology 163(6): 1282-1290. doi:10.1111/j.1365-2133.2010.09992.x.
4. Rossi MT, Venturini M, Zanca A, Arisi M, Fusano M, Sottini A, Serana F, Imberti L, Calzavara-Pinton P (2018) Serum levels of tumor necrosis factor-alpha in patients with psoriasis before, during and after narrow-band UVB phototherapy. Giornale Italiano di Dermatologia e Venereologia 153(1):1-4. doi:10.23736/S0392-0488.17.05688-7.
5. Johnson-Huang LM, Suárez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, Lowes MA (2010) Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. Journal of Investigative Dermatology 130(11): 2654-2663.
6. Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005(5): 273-279. doi:10.1155/MI.2005.273.
7. Krueger GG, Langley RG, Leonardi C, et al (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356(6):580-592. doi:10.1056/NEJMoa062382.
8. Ogawa E, Sato Y, Minagawa A, Okuyama R (2018) Pathogenesis of psoriasis and development of treatment. The Journal of Dermatology 45(3):264-272. doi: 10.1111/1346-8138.14139.
9. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M et al (2011) Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131(3): 677-687. doi:10.1038/jid.2010.340.
Article Sidebar
